Loading clinical trials...
Loading clinical trials...
This prospective observational study will evaluate the efficacy and safety of second-line Tarceva (erlotinib) in patients with previously treated advanced non-small cell lung cancer with confirmed wil...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Hoffmann-La Roche
NCT07098988 · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
NCT06627647 · Non-squamous Non-small Cell Lung Cancer
NCT06417008 · Non-Squamous Non-Small Cell Lung Cancer
NCT06311721 · Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06028633 · Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, and more
Vitoria-Gasteiz, Alava
Elda, Alicante
Mahon, Balearic Islands
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions